Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 311,003
  • Shares Outstanding, K 68,806
  • Annual Sales, $ 20,760 K
  • Annual Income, $ -132,490 K
  • 60-Month Beta 3.07
  • Price/Sales 15.32
  • Price/Cash Flow N/A
  • Price/Book 1.23
Trade CCCC with:

Options Overview Details

View History
  • Implied Volatility 73.77% ( -13.10%)
  • Historical Volatility 62.08%
  • IV Percentile 20%
  • IV Rank 14.27%
  • IV High 401.71% on 02/05/24
  • IV Low 19.20% on 05/29/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 128
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 12,739
  • Open Int (30-Day) 12,493

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.37
  • Number of Estimates 5
  • High Estimate -0.18
  • Low Estimate -0.46
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +49.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.91 +16.11%
on 06/18/24
5.14 -11.67%
on 06/12/24
-0.30 (-6.20%)
since 06/03/24
3-Month
3.91 +16.11%
on 06/18/24
8.08 -43.81%
on 04/12/24
-3.36 (-42.53%)
since 04/03/24
52-Week
1.06 +328.30%
on 12/06/23
11.88 -61.78%
on 03/04/24
+1.71 (+60.42%)
since 07/03/23

Most Recent Stories

More News
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

/CNW/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...

ONCY : 0.9897 (-0.03%)
TCRX : 5.73 (-3.37%)
BMY : 40.50 (+0.12%)
PDSB : 2.89 (-2.03%)
CCCC : 4.54 (+0.44%)
ONC.TO : 1.37 (+1.48%)
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...

ONCY : 0.9897 (-0.03%)
ONC.TO : 1.37 (+1.48%)
TCRX : 5.73 (-3.37%)
BMY : 40.50 (+0.12%)
PDSB : 2.89 (-2.03%)
CCCC : 4.54 (+0.44%)
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial – – Phase 1/2 Clinical Trial for CFT8634, a...

CCCC : 4.54 (+0.44%)
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors

– Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and Clinical Development in Support of Successful Product Launches – ...

CCCC : 4.54 (+0.44%)
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in...

CCCC : 4.54 (+0.44%)
C4 Therapeutics is Now Oversold (CCCC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

CCCC : 4.54 (+0.44%)
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected...

CCCC : 4.54 (+0.44%)
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

– Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee...

CCCC : 4.54 (+0.44%)
Promising Developments in Treating Multiple Myeloma Coming at This Year’s AACR Meeting

VANCOUVER – USA News Group –According to a report from ResearchAndMarkets.com, total cases of the uncommon but deadly blood cancer, multiple myeloma, will continue to rise by 2030. Treatment for the...

ONCY : 0.9897 (-0.03%)
ONC.TO : 1.37 (+1.48%)
CGEN : 1.7200 (+1.78%)
CCCC : 4.54 (+0.44%)
AMGN : 310.77 (-0.08%)
JNJ : 146.17 (+0.10%)
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

- Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – -...

CCCC : 4.54 (+0.44%)

Business Summary

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics...

See More

Key Turning Points

3rd Resistance Point 5.22
2nd Resistance Point 5.03
1st Resistance Point 4.78
Last Price 4.54
1st Support Level 4.34
2nd Support Level 4.15
3rd Support Level 3.90

See More

52-Week High 11.88
Fibonacci 61.8% 7.75
Fibonacci 50% 6.47
Fibonacci 38.2% 5.19
Last Price 4.54
52-Week Low 1.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar